Predicting invasiveness and disease-specific survival in upper tract urothelial carcinoma: identifying relevant clinical tumour characteristics.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 01 01 2019
accepted: 04 04 2019
pubmed: 25 4 2019
medline: 18 3 2020
entrez: 25 4 2019
Statut: ppublish

Résumé

The aim of this prospective study was to identify the tumour characteristics that are associated with invasiveness and those that are relevant for disease-specific survival (DSS) in upper tract urothelial carcinoma, UTUC. From a prospective consecutive cohort of patients with suspicion of UTUC, those who were diagnosed with UTUC using URS prior to rNU between 2005 and 2012 were included. Tumour characteristics were analysed for prediction of invasiveness and association with DSS. Stages were categorised as superficial (pTa-1 and CIS only) or invasive (≥  pT2). Tumours were graded according to WHO 1999 classification. DSS was analysed regarding possible association with stage, grade, size, multifocality, location, ploidy and rate of proliferation. Associations were tested using Fisher's exact test, Pearson Chi-square or Cox's regression. Kaplan-Meier survival curves were constructed. Forty-five consecutive patients were included, and 43 of them were included in the final analyses because their rNU specimens were available for reassessment. The only tumour characteristics that were significantly associated with stage were tumour grade (P < 0.001), DNA ploidy (P = 0.045) and rate of proliferation (P = 0.004). No association with stage was noted for size, multifocality or location. Grade, stage and rate of proliferation were associated with DSS. Grade, DNA ploidy and S-phase fraction were the only tumour characteristics associated with stage in our study. However, DNA ploidy was not associated with DSS. The prognostic factors that we identified were tumour grade, stage, and S-phase fraction.

Identifiants

pubmed: 31016451
doi: 10.1007/s00345-019-02760-4
pii: 10.1007/s00345-019-02760-4
pmc: PMC6825649
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2335-2342

Références

Int J Urol. 2003 Dec;10(12):627-30
pubmed: 14633064
J Urol. 2018 Jan;199(1):66-73
pubmed: 28818526
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
BJU Int. 2012 Jan;109(1):77-82
pubmed: 21631698
J Urol. 2009 Feb;181(2):524-31; discussion 531
pubmed: 19100576
Oncogene. 2001 Aug 9;20(35):4910-5
pubmed: 11521204
J Urol. 2016 Dec;196(6):1749-1755
pubmed: 27475968
Int Urol Nephrol. 2014 Mar;46(3):563-9
pubmed: 24057684
J Urol. 2018 Jun;199(6):1440-1445
pubmed: 29427584
Urology. 2007 Aug;70(2):252-6
pubmed: 17826484
BJU Int. 2009 Apr;103(8):1052-7
pubmed: 18990140
BJU Int. 2012 Dec;110(11):1618-26
pubmed: 22458598
Scand J Urol. 2017 Apr;51(2):137-145
pubmed: 28385123
Clin Genitourin Cancer. 2016 Dec;14(6):e609-e615
pubmed: 27262370
BJU Int. 2017 Feb;119(2):289-297
pubmed: 27611622
J Urol. 2000 Jan;163(1):52-5
pubmed: 10604312
Arch Pathol Lab Med. 2013 Mar;137(3):400-7
pubmed: 23451751
Cytometry. 1991;12(7):614-21
pubmed: 1723676
Urology. 2012 Mar;79(3):615-9
pubmed: 22386411
Eur Urol. 2018 Jan;73(1):111-122
pubmed: 28867446
J Urol. 1997 Jan;157(1):33-7
pubmed: 8976209
J Urol. 2010 Jul;184(1):69-73
pubmed: 20478585
Urology. 2005 Aug;66(2):274-8
pubmed: 16098355
Urology. 2003 Jun;61(6):1146-50
pubmed: 12809884
J Endourol. 2008 Jun;22(6):1237-9
pubmed: 18578656
BJU Int. 2012 Sep;110(5):614-28
pubmed: 22471401
J Endourol. 2008 Jan;22(1):71-6
pubmed: 18315477
BJU Int. 2011 Sep;108(5):701-5
pubmed: 21320275

Auteurs

Camilla Malm (C)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Urology, Stockholm South General Hospital, Stockholm, Sweden.

Alexandra Grahn (A)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Division of Urology, Karolinska University Hospital, Stockholm, Sweden.

Georg Jaremko (G)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Pathology and Cytology, Karolinska University Hospital Solna, Stockholm, Sweden.

Bernhard Tribukait (B)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Marianne Brehmer (M)

Division of Urology, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden. marianne.brehmer@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH